Karyopharm Therapeutics’ (KPTI) Outperform Rating Reaffirmed at Royal Bank of Canada

Karyopharm Therapeutics (NASDAQ:KPTI)‘s stock had its “outperform” rating reiterated by analysts at Royal Bank of Canada in a research note issued to investors on Monday,Benzinga reports. They currently have a $3.00 target price on the stock. Royal Bank of Canada’s price objective would suggest a potential upside of 360.12% from the company’s current price.

Several other brokerages also recently commented on KPTI. StockNews.com downgraded shares of Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, November 22nd. Piper Sandler raised their price target on shares of Karyopharm Therapeutics from $4.00 to $5.00 and gave the company an “overweight” rating in a research note on Wednesday, November 6th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $7.00 price target on shares of Karyopharm Therapeutics in a research note on Wednesday, January 15th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $5.00.

Karyopharm Therapeutics Trading Up 3.3 %

NASDAQ:KPTI traded up $0.02 on Monday, hitting $0.65. The company had a trading volume of 530,055 shares, compared to its average volume of 758,905. The stock has a market capitalization of $82.28 million, a price-to-earnings ratio of -0.57 and a beta of 0.06. The firm has a 50 day moving average of $0.69 and a two-hundred day moving average of $0.78. Karyopharm Therapeutics has a 52 week low of $0.58 and a 52 week high of $1.70.

Institutional Investors Weigh In On Karyopharm Therapeutics

A number of large investors have recently bought and sold shares of the stock. Exchange Traded Concepts LLC lifted its stake in shares of Karyopharm Therapeutics by 34.9% in the third quarter. Exchange Traded Concepts LLC now owns 218,791 shares of the company’s stock valued at $182,000 after buying an additional 56,613 shares in the last quarter. FMR LLC lifted its stake in shares of Karyopharm Therapeutics by 26.1% in the third quarter. FMR LLC now owns 369,723 shares of the company’s stock valued at $307,000 after buying an additional 76,510 shares in the last quarter. AQR Capital Management LLC lifted its stake in shares of Karyopharm Therapeutics by 494.5% in the second quarter. AQR Capital Management LLC now owns 748,020 shares of the company’s stock valued at $649,000 after buying an additional 622,194 shares in the last quarter. Geode Capital Management LLC lifted its stake in shares of Karyopharm Therapeutics by 3.3% in the third quarter. Geode Capital Management LLC now owns 1,355,392 shares of the company’s stock valued at $1,125,000 after buying an additional 43,856 shares in the last quarter. Finally, GSA Capital Partners LLP lifted its stake in shares of Karyopharm Therapeutics by 80.6% in the third quarter. GSA Capital Partners LLP now owns 1,775,700 shares of the company’s stock valued at $1,474,000 after buying an additional 792,283 shares in the last quarter. 66.44% of the stock is currently owned by institutional investors and hedge funds.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).